spacer
home > ict > winter 2009 > from dumb to smart
PUBLICATIONS
International Clinical Trials

From Dumb to Smart

BACKGROUND

The business fundamentals of conducting clinical research have changed dramatically over the last few years. Although not quite as well-publicised as the recent events in world financial markets, the fundamentals of the industry have steadily eroded. Clinical trials are more expensive, take longer to run, and patient recruitment is harder than ever, to give just a few examples.

Even more worrying is the fact that the industry has been content to operate in the dark, with few objective metrics about the convoluted internal operations critical to planning and conducting clinical trials. For example, the Six Sigma methodologies that can be applied to the clinical development process have only recently been recognised by the industry, despite the fact that Six Sigma provides objective criteria that helps to measure the value of decisions. These decisions commit hundreds of millions of dollars to development programmes.

Furthermore, job cuts are occurring with increasing regularity, as are dramatic outsourcing arrangements and billion-dollar acquisitions. Unfortunately, while these big announcements garner a lot of attention, the actions often obscure the need to improve the efficiency and effectiveness of day-to-day clinical operations. In fact, the decisions related to crucial development activities that determine the successes of specific clinical programmes – and the overall health of the industry – are often overlooked.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer
Edward Seguine is General Manager, Trial Planning Solutions, at Medidata Solutions, and is responsible for strategy development and execution. As a member of the senior management team at Medidata, Ed oversees all development, implementation and commercialisation activities for Medidata CRO Contractor, Medidata Designer, Medidata Grants Manager and the proprietary benchmark data these products rely on. Previously, Ed served as CEO of Fast Track Systems Inc, after moving from Eli Lilly, where he was instrumental in establishing both e.Lilly and Lilly Ventures. Ed is active in CDISC as the chair-elect of the Industry Advisory Board, a non-voting member of the CDISC board, and Financial Oversight Committee. In addition, he has written several articles and is a periodic speaker at industry events. Ed earned his BBA from Brigham Young University and MBA from Indiana University.
spacer
Edward Seguine
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

ERT Virtual Visit Capabilities Keep Clinical Trials on Track during COVID-19

ERT, a global data and technology company that captures critical endpoint data while minimizing uncertainty and risk in clinical trials, today announced a Virtual Visit solution that enables the continuation of clinical trials during and after current global stay-at-home mandates. As a result of COVID-19, many clinical trials have been delayed as healthcare providers focus their efforts on patients who require urgent care, which limits clinical trial patients’ access to investigative sites for routine visits.
More info >>

White Papers

Keeping Abreast of the Competitive Environment in Clinical Development

Thomson Reuters

Strategic management of a therapy area requires hard decisions to be made about which programs to invest in and which to let go. Understanding the rapidly changing competitive environment for your drug candidates is a key input into these decisions. It is easy to lose track of the broader picture when a clinical program is in progress and get blindsided by external events.
More info >>

 
Industry Events

Formulation and Drug Delivery Series UK

8-9 July 2020, Oxford Global

This event brings together leading formulation, drug delivery and biologics manufacturing experts from around the world across two days. The panel of prominent industry leaders and world-leading scientists will share the latest case studies, innovative developments for novel therapeutic products and strategies for drug development.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement